Program
taldefgrobep alfa
Also written as “RO7239361”, “Taldefgrobep Alfa” and “BMS-986089”.
Its studies are mostly in Muscular Atrophy, Spinal · Obesity · Muscular Dystrophy, Duchenne · Muscular Dystrophies, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 40 open or running | phase 3since Jan 27, 2017 | May 16, 2014 | none ahead |
| Biohaven Pharmaceuticals | 11 open or running | phase 3since Apr 14, 2022 | Apr 14, 2022 | none ahead |
| Biohaven Therapeutics | 11 open or running | phase 2since Dec 4, 2025 | Dec 4, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 16, 2014First study: phase 1 study in Healthy AdultsNew to Hoffmann-La RocheHoffmann-La Roche · NCT02145234 · 140 enrolled · United States
- Jul 29, 2015Phase 2 study in Muscular DystrophiesHoffmann-La Roche · NCT02515669 · 43 enrolled · United States, Canada
- Jan 27, 2017Phase 3 study in Muscular Dystrophy, DuchenneHoffmann-La Roche · NCT03039686 · 166 enrolled · United States, Argentina, Australia and more
- Mar 29, 2017Phase 1 study in HealthyHoffmann-La Roche · NCT03100630 · 99 enrolled · United States
- Apr 14, 2022Biohaven Pharmaceuticals's first study: phase 3 study in Muscular Atrophy, SpinalNew to Biohaven PharmaceuticalsBiohaven Pharmaceuticals · NCT05337553 · 269 enrolled · United States, Belgium, Czechia and more
- Dec 4, 2025Biohaven Therapeutics's first study: phase 2 study in ObesityNew to Biohaven TherapeuticsBiohaven Therapeutics · NCT07281495 · 150 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07281495Obesity · United States | 2 | Active, not recruiting | Biohaven Therapeutics | Sep 2026 | 150 |
| NCT05337553Muscular Atrophy, Spinal · United States, Belgium, Czechia and more | 3 | Active, not recruiting | Biohaven Pharmaceuticals | Sep 25, 2024 | 269 |
| NCT03100630Healthy · United States | 1 | Completed | Hoffmann-La Roche | Oct 17, 2017 | 99 |
| NCT03039686Muscular Dystrophy, Duchenne · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Apr 28, 2020 | 166 |
| NCT02515669Muscular Dystrophies · United States, Canada | 2 | Terminated | Hoffmann-La Roche | Feb 8, 2018 | 43 |
| NCT02145234Healthy Adults · United States | 1 | Completed | Hoffmann-La Roche | Feb 29, 2016 | 140 |
How it is read
Names in the registry
- “RO7239361”, 3 entries
- “taldefgrobep alfa”, 2 entries
- “Taldefgrobep Alfa”, 2 entries
- “BMS-986089”, 1 entry
Conditions, from the studies’ own filings
- Muscular Atrophy, Spinal, 1 study
- Obesity, 1 study
- Muscular Dystrophy, Duchenne, 1 study
- Muscular Dystrophies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.